Updated Results of 3,050 Non-melanoma Skin Cancer (NMSC) Lesions in 1725 Patients Treated with High Resolution Dermal Ultrasound-Guided Superficial Radiotherapy, A Multi-institutional Study - Moloney, Mairead; Kaczmarksi, Peter; Zheng, Songzhu; Malik, Ariana; Ladd, Daniel; Serure, Donna; Yu, Lio (medRxiv, 2023)
Background Image-guided superficial radiation therapy (IGSRT) using a high resolution dermal ultrasound, is becoming an attractive non-surgical curative treatment option for nonmelanoma skin cancer (NMSC). We previously reported IGSRT treatment results from a multi-institutional study of 1616 patients with 2917 NMSC lesions (Yu et al. Oncol Ther 2021, https://doi.org/10.1007/s40487-021-00138-4) showing excellent local control (LC) of 99.3% with mean follow-up of 69.8 weeks (16.06 months).Methods This abstract analyzes an additional 93 patients with 133 lesions, updates previous findings with longer follow-up, using Kaplan-Meier statistics, and performs subgroup analysis. A total of 1709 patients with 3,050 Stage 0, I, and II NMSC lesions treated from 2017 to 2020 were retrospectively analyzed.Results Lesions received a median of 20 fractions of 50, 70, or 100 kilovoltage(kV) IGSRT using image guidance. Average follow-up was 25.06 months (108.9 weeks) with a maximum follow up of 65.6 months (285.0 weeks) for the entire cohort. 68 patients expired from unrelated causes with no-evidence of disease (NED) at last follow-up prior to death, thus Disease-Free-Survival (DFS) was 100%. Overall, 3,027 of 3,050 lesions achieved an absolute LC of 99.2%. Overall absolute LC for BCC, SCC, and SCCis was 99.0%, 99.2%, and 99.8%, respectively. No additional late complications were found to date as of January 2022.Discussion These updated results demonstrate that IGSRT continues to achieve a high level of LC with low complication rates. IGSRT should be considered an attractive first-line option for the non-surgical treatment of NMSC.Competing Interest StatementMairead Moloney has no conflicts of interest to disclose. Peter Kaczmarksi has no conflicts of interest to disclose. Songzhu Zheng has no conflicts of interest to disclose. Ariana Malik has no conflicts of interest to disclose. Dr. Daniel Ladd is the Chief Medical Officer for Skin Cure Oncology and has received research, speaking and/or consulting support from Skin Cure Oncology. Dr. Ladd is also the Medical Director and Founder of Tru-Skin Dermatology. Dr. Donna Serure has no conflicts of interest to disclose. Dr. Lio Yu is the National Radiation Oncologist for Skin Cure Oncology and has received research, speaking and/or consulting support from Skin Cure Oncology. He has served on an advisory board for Bayer Pharmaceuticals previously.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of WCG IRB waived ethical approval for this work. WCG IRBs IRB Affairs Department reviewed the study under the Common Rule and applicable guidance. The response state this study is exempt under 45 CFR | 46.104(d)(4), because the research involves the use of identifiable private information; and information is recorded by the investigator in such a manner that the identity of the human subjects cannot readily by ascertained directly or through identifiers linked to the subjects, the investigator does not contact the subjects, and the investigator will not re-identify subjects. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesDeidentified data are available on request from Dr. Lio Yu at lio.yuatprotonmail.com. Data will be available for request with publication for period of at least 1 year.